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Most	  tumors	  display	  increased	  glucose	  metabolism	  compared	  to	  that	  of	  
normal	  tissues.	  	  The	  preferential	  conversion	  of	  glucose	  to	  lactate	  in	  cancer	  
cells	  (the	  Warburg	  Effect)	  has	  been	  emphasized1;	  however,	  the	  extent	  to	  which	  
metabolic	  fluxes	  originating	  from	  glucose	  are	  utilized	  for	  alternative	  
processes	  is	  poorly	  understood2,3.	  	  Here	  we	  used	  a	  combination	  of	  mass	  
spectrometry	  and	  NMR	  with	  stable	  isotope	  labeling	  to	  investigate	  the	  
alternate	  pathways	  derived	  from	  glucose	  metabolism	  in	  cancer	  cells.	  	  We	  
found	  that	  in	  some	  cancer	  cells,	  a	  relatively	  large	  amount	  of	  glycolytic	  carbon	  
is	  diverted	  into	  serine	  and	  glycine	  biosynthesis	  through	  phosphoglycerate	  
dehydrogenase	  (PHGDH).	  	  A	  bioinformatics	  analysis	  of	  3131	  human	  cancers	  
revealed	  that	  the	  gene	  PHGDH	  at	  1p12	  is	  recurrently	  amplified	  in	  a	  genomic	  
region	  of	  focal	  copy	  number	  gain	  most	  commonly	  found	  in	  melanoma	  in	  which	  
amplification	  was	  associated	  with	  increased	  protein	  expression.	  	  Decreased	  
PHGDH	  expression	  by	  RNA	  interference	  impaired	  growth	  and	  flux	  into	  serine	  
metabolism	  in	  PHGDH-­‐amplified	  cell	  lines.	  	  Increased	  expression	  was	  also	  
associated	  with	  breast	  cancer	  subtypes	  and	  ectopic	  expression	  of	  PHGDH	  in	  
mammary	  epithelial	  cells	  (MCF-­‐10a)	  disrupted	  acinar	  morphogenesis,	  
induced	  loss	  of	  polarity,	  and	  preserved	  the	  viability	  of	  the	  extracellular	  
matrix-­‐deprived	  cells,	  each	  being	  phenotypic	  alterations	  that	  may	  predispose	  
cells	  to	  transformation.	  	  Our	  findings	  demonstrate	  that	  altered	  metabolic	  flux	  
from	  glucose	  into	  a	  specific	  alternate	  pathway	  can	  be	  selected	  during	  tumor	  
development	  and	  may	  contribute	  to	  the	  pathogenesis	  of	  human	  cancer.	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   Most	  tumors	  and	  cancer	  cell	  lines	  metabolize	  large	  amounts	  of	  glucose	  through	  a	  fermentative	  metabolism	  characterized	  by	  lactate	  production	  even	  in	  the	  presence	  of	  oxygen	  (aerobic	  glycolysis)1.	  	  One	  idea	  is	  that	  aerobic	  glycolysis	  allows	  cancer	  cells	  to	  adapt	  metabolism	  to	  satisfy	  specific	  biosynthetic	  requirements2,3.	  	  This	  hypothesis	  is	  buttressed	  by	  evidence	  indicating	  that	  the	  final	  step	  in	  glycolysis	  catalyzed	  by	  pyruvate	  kinase	  is	  inhibited	  in	  cancer	  cells4,5.	  	  The	  selection	  for	  lower	  pyruvate	  kinase	  activity	  may	  allow	  glycolytic	  intermediates	  upstream	  of	  pyruvate	  kinase	  to	  be	  diverted	  into	  other	  metabolic	  pathways	  in	  cancer	  cells.	  	  However,	  it	  is	  not	  clear	  whether	  utilization	  of	  specific	  alternative	  pathways	  is	  necessary	  for	  cancer	  cell	  proliferation,	  nor	  whether	  differences	  in	  individual	  fluxes	  contribute	  to	  the	  development	  of	  cancers.	  	  Metabolomics	  in	  conjunction	  with	  stable	  isotope	  labeling	  of	  glucose	  allows	  for	  an	  unbiased	  interrogation	  of	  the	  pathways	  originating	  from	  glucose	  metabolism.	  	  	  	  	  To	  better	  understand	  the	  diversity	  of	  glucose	  metabolism,	  we	  utilized	  sensitivity-­‐enhanced	  NMR	  based	  2-­‐dimensional	  heteronuclear	  single	  quantum	  correlation	  spectroscopy	  (HSQC)	  to	  quantify	  steady	  state	  levels	  of	  glucose-­‐derived	  metabolites	  in	  HEK293T	  cells	  following	  24	  hours	  of	  labeling	  with	  [U-­‐13C]-­‐glucose6.	  	  We	  discretized	  the	  spectra	  and	  computed	  the	  intensities	  of	  each	  resulting	  bin	  (Fig	  1A,	  Table	  S1).	  	  Consistent	  with	  previous	  descriptions	  of	  glucose	  metabolism	  in	  cancer	  cells,	  two	  of	  the	  four	  highest	  intensity	  bins	  contained	  lactate	  peaks	  (Fig	  1A).	  	  Surprisingly,	  a	  bin	  containing	  13C-­‐glycine	  was	  nearly	  as	  abundant	  as	  that	  containing	  
13C-­‐lactate	  (Fig	  1A).	  	  To	  determine	  whether	  this	  result	  was	  general	  to	  all	  cultured	  cells	  as	  has	  been	  suggested7-­‐9,	  we	  carried	  out	  the	  [U-­‐13C]	  glucose	  HSQC	  experiment	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in	  two	  other	  exponentially	  growing	  cell	  lines:	  H1299	  an	  epithelial	  lung	  cancer	  cell	  line	  and	  MCF-­‐10a,	  a	  non-­‐tumorigenic	  mammary	  epithelial	  cell	  line.	  	  In	  H1299	  cells,	  we	  detected	  smaller	  relative	  quantities	  of	  13C	  labeled	  glycine	  (Fig	  1B)	  while	  in	  MCF-­‐10a	  cells,	  no	  13C	  labeled	  glycine	  was	  observed	  (Fig	  1B).	  	  Together,	  these	  data	  indicate	  that	  cell	  lines	  display	  variability	  in	  glucose	  metabolism	  with	  differences	  in	  relative	  flux	  of	  glucose	  to	  glycine.	  Glycine	  can	  be	  generated	  from	  glucose	  via	  diversion	  of	  the	  glycolytic	  intermediate,	  3-­‐phosphoglycerate	  (3PG),	  into	  the	  serine	  synthesis	  pathway	  and	  by	  the	  ultimate	  conversion	  of	  serine	  to	  glycine	  (Fig	  1C)10.	  	  The	  first	  committed	  step	  in	  this	  pathway	  is	  the	  oxidation	  of	  3PG	  to	  3-­‐phosphohydroxypyruvate	  (pPYR)	  by	  the	  enzyme	  phosphoglycerate	  dehydrogenase	  (PHGDH)11.	  	  pPYR	  is	  transaminated	  by	  phosphoserine	  aminotransferase	  (PSAT)	  with	  glutamate	  as	  a	  nitrogen	  donor	  to	  form	  phosphoserine	  (pSER)	  and	  alpha-­‐ketoglutarate	  (αKG),	  and	  pSER	  is	  then	  dephosphorylated	  by	  phosphoserine	  phosphatase	  (PSPH)	  to	  form	  serine	  (Fig	  1C).	  	  Serine	  (SER)	  can	  be	  directly	  converted	  to	  glycine	  (GLY)	  by	  donation	  of	  a	  carbon	  into	  the	  folate	  pool.	  	  This	  pathway	  defines	  a	  branching	  point	  for	  3PG	  from	  glycolysis,	  initialized	  by	  the	  enzymatic	  activity	  of	  PHGDH,	  that	  could	  otherwise	  be	  metabolized	  to	  pyruvate,	  alanine,	  and	  lactate.	  	  Serine	  and	  glycine	  are	  intermediates	  in	  pathways	  for	  the	  synthesis	  of	  other	  amino	  acids,	  as	  well	  as	  lipids	  and	  nucleic	  acids.	  	  Flux	  into	  this	  pathway	  has	  been	  observed	  in	  cancer	  cells	  but	  its	  cancer	  context,	  stoichiometry,	  requirement	  for	  cell	  growth,	  and	  potential	  to	  promote	  cell	  transformation	  have	  not	  been	  addressed7-­‐9.	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To	  further	  interrogate	  glucose	  metabolism	  in	  cells,	  we	  monitored	  the	  time	  course	  of	  conversion	  of	  [U-­‐13C]	  glucose	  to	  other	  metabolites	  using	  targeted	  liquid	  chromatography/mass	  spectrometry	  (LC/MS)12	  in	  HEK293T	  cells.	  13C-­‐labeled	  glucose	  incorporation	  into	  thirteen	  metabolites,	  in	  multiple	  pathways,	  was	  detected	  over	  the	  30-­‐minute	  time	  course	  (Fig	  1D).	  	  The	  time	  required	  for	  labeled	  carbon	  to	  reach	  steady	  state	  in	  a	  pathway	  is	  a	  direct	  measurement	  of	  pathway	  flux.	  	  The	  data	  in	  Fig	  1E	  reveal	  that	  13C	  incorporation	  into	  pSER	  (13C-­‐pSER)	  reaches	  steady	  state	  at	  a	  time	  scale	  comparable	  to	  the	  time	  for	  phosphoenolpyruvate	  (PEP)	  to	  reach	  steady	  state,	  suggesting	  that	  the	  relative	  fluxes	  are	  comparable.	  	  The	  13C-­‐pSER	  labeling	  accompanied	  labeling	  of	  serine	  (Fig	  S1A)	  and	  labeling	  of	  serine	  was	  also	  confirmed	  using	  GC/MS	  by	  measuring	  pool	  sizes	  of	  incorporation	  of	  [α-­‐15N]	  glutamine	  into	  amino	  acids	  (Fig	  S1B).	  	  These	  data	  are	  in	  agreement	  with	  our	  NMR	  experiments	  suggesting	  that	  a	  substantial	  fraction	  of	  glucose	  is	  diverted	  from	  3PG	  into	  the	  serine	  and	  glycine	  biosynthetic	  pathway	  in	  these	  cells.	  	  To	  measure	  the	  total	  amount	  of	  glucose-­‐derived	  serine,	  we	  cultured	  HEK293T	  cells	  in	  uniformly	  labeled	  13C	  glucose	  and	  measured	  metabolites	  from	  cell	  extracts	  using	  LC/MS.	  	  The	  total	  amount	  of	  labeled	  serine	  was	  found	  to	  be	  about	  one	  half,	  and	  this	  value	  was	  commensurate	  with	  the	  relative	  amount	  of	  glucose	  incorporation	  into	  nucleotides	  and	  nucleotide	  intermediates	  with	  the	  remaining	  fraction	  coming	  from	  other	  nutrients	  and	  salvage	  pathways	  (Fig	  1F).	  	  We	  verified	  expression	  of	  PHGDH	  by	  western	  blot	  (Fig	  1G)	  and	  observed	  greater	  PHGDH	  protein	  expression	  in	  HEK293T	  cells	  compared	  to	  levels	  of	  expression	  observed	  in	  H1299	  and	  MCF10a	  cells.	  	  Thus,	  the	  increased	  synthesis	  of	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glycine	  from	  glucose	  in	  HEK293T	  cells	  is	  associated	  with	  higher	  PHGDH	  protein	  levels	  and	  the	  absence	  of	  its	  detection	  in	  MCF10a	  cells	  corresponds	  to	  approximately	  30-­‐fold	  lower	  protein	  expression.	  	  	  The	  selective	  diversion	  of	  glucose	  metabolism	  into	  serine	  metabolism	  through	  PHGDH	  suggested	  that	  there	  might	  be	  a	  context	  in	  which	  selective	  pressure	  exists	  for	  tumors	  to	  increase	  PHGDH	  activity.	  	  One	  mechanism	  that	  can	  enhance	  PHGDH	  activity	  is	  an	  increase	  in	  the	  copy	  number	  at	  the	  genomic	  locus	  containing	  the	  PHGDH	  gene.	  	  We	  identified	  PHGDH	  in	  a	  study	  of	  a	  pooled	  analysis	  of	  somatic	  copy	  number	  alterations	  (SCNA)	  as	  a	  frequently	  amplified	  gene	  across	  3131	  cancer	  samples13.	  	  Compared	  to	  the	  false	  discovery	  rate	  (q-­‐value)	  obtained	  from	  the	  background	  rate	  of	  SCNA	  in	  cancer,	  PHGDH	  was	  found	  in	  a	  peak	  of	  a	  region	  of	  chromosome	  1p	  (1p12)	  that	  exhibits	  recurring	  copy	  number	  gain	  in	  16%	  of	  all	  cancers	  (Supplementary	  Table	  S2).	  	  No	  known	  oncogenes	  are	  contained	  in	  the	  peak	  region	  of	  five	  genes	  (PHGDH,	  REG4,	  HMGCS2,	  NBPF7,	  ADAM30)	  at	  this	  locus.	  	  PHGDH	  is	  located	  in	  one	  of	  four	  peak	  regions	  of	  chromosome	  1p	  (q	  =	  1.12e-­‐9)	  (Fig	  2A,	  left).	  	  Two	  of	  the	  three	  high-­‐scoring	  peaks	  contain	  the	  oncogenes	  MYCL1	  at	  1p34	  (q	  =	  1.7e-­‐14)	  and	  JUN	  at	  1p32	  (q	  =	  8.55e-­‐7)	  (Fig	  2A,	  left).	  	  The	  copy	  number	  intensity	  of	  150	  cancers	  sorted	  by	  highest	  PHGDH	  copy	  number	  (Fig	  2A,	  middle)	  was	  plotted	  along	  chromosome	  1p	  showing	  that	  most	  samples	  containing	  PHGDH	  copy	  number	  gain	  have	  the	  genomic	  amplification	  localized	  near	  the	  1p12	  region.	  	  An	  inspection	  of	  the	  genomic	  region	  containing	  PHGDH	  (Fig	  2A,	  right)	  illustrated	  the	  localized,	  amplification	  within	  the	  coding	  region	  of	  the	  PHGDH	  gene.	  	  Amplification	  was	  found	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most	  commonly	  in	  melanoma	  (Fig	  S2)	  at	  40%	  frequency	  in	  a	  three-­‐gene	  peak	  region	  (q	  =	  1.93e-­‐5)	  with	  HMGCS2	  and	  REG4.	  	  	  	  We	  first	  examined	  T.T.	  cells,	  an	  esophageal	  squamous	  cell	  carcinoma	  cell	  line	  that	  contained	  a	  highly	  focal	  copy	  number	  gain	  of	  PHGDH13	  as	  determined	  by	  SNP	  array,	  and	  carried	  out	  fluorescence	  in	  situ	  hybridization	  (FISH)	  to	  verify	  copy	  number	  gain	  (Fig	  2B).	  	  Focal	  copy	  number	  gain	  in	  PHGDH	  suggested	  that	  expression	  might	  be	  important	  for	  proliferation	  in	  these	  cells	  and	  stable	  PHGDH	  knockdown	  using	  shRNA	  reduced	  the	  proliferation	  rate	  (Fig	  2B).	  	  To	  test	  whether	  the	  decreased	  proliferation	  was	  due	  to	  alterations	  in	  the	  ability	  to	  utilize	  the	  serine	  biosynthesis	  pathway,	  we	  created	  cell	  lines	  with	  decreased	  expression	  of	  downstream	  enzymes	  PSAT	  and	  PSPH	  and	  found	  that	  shRNA-­‐mediated	  knockdown	  of	  these	  enzymes	  resulted	  in	  similar	  decreases	  in	  proliferation	  (Fig	  2B).	  	  	  	  Since	  PHGDH	  amplification	  in	  a	  single	  tumor	  type	  was	  most	  commonly	  found	  in	  melanoma,	  we	  assessed	  PHGDH	  expression	  and	  copy	  number	  gain	  in	  human	  melanoma	  tissue	  samples.	  	  Immunohistochemistry	  (IHC)	  was	  used	  to	  measure	  PHGDH	  expression	  in	  a	  tissue	  collection	  of	  human	  melanoma	  and	  high	  expression	  (IHC	  score	  >	  1)	  was	  observed	  in	  21%	  of	  the	  samples	  (Fig	  S3A,	  B).	  	  We	  then	  used	  FISH	  to	  probe	  relative	  PHGDH	  copy	  number	  in	  a	  subset	  of	  42	  of	  these	  samples	  (Fig	  S3C).	  	  PHGDH	  copy	  number	  gain	  was	  observed	  in	  21	  of	  the	  42	  samples;	  however,	  16	  of	  these	  samples	  also	  contained	  an	  equal	  increased	  number	  of	  copies	  of	  a	  probe	  sequence	  adjacent	  to	  the	  centromere,	  indicating	  either	  polysomy	  or	  that	  the	  amplified	  region	  also	  contained	  the	  pericentromeric	  region	  of	  chromosome	  1p.	  	  Five	  tumors	  exhibited	  copy	  number	  gain	  with	  the	  number	  of	  copies	  greater	  than	  the	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number	  of	  pericentromeric	  probes	  (Fig	  2C).	  	  It	  was	  observed	  that	  each	  sample	  with	  relative	  gain	  had	  high	  expression	  by	  IHC	  (Fig	  2C),	  indicating	  that	  PHGDH	  copy	  number	  gain	  and	  amplification	  associates	  with	  significant	  protein	  overexpression	  in	  human	  melanoma	  (p	  =	  0.0045,	  Fisher’s	  exact	  test,	  two-­‐tailed).	  	  	  	  	  We	  next	  investigated	  whether	  melanoma	  cell	  lines	  containing	  PHGDH	  copy	  number	  gain	  would	  be	  sensitive	  to	  decreased	  expression	  of	  PHGDH.	  	  Three	  tumor-­‐derived	  human	  melanoma	  cell	  lines	  (WM1266-­‐3,	  Malme-­‐3M,	  and	  SK-­‐Mel28)	  with	  1p12	  gain	  were	  obtained	  along	  with	  two	  additional	  melanoma	  cell	  lines	  (Gak,	  Carney)14.	  	  Pairs	  of	  cell	  lines	  containing	  shRNA	  targeting	  PHGDH	  and	  GFP	  as	  a	  control	  were	  created	  for	  each	  cell	  line	  (Fig	  3A,	  left).	  	  Each	  of	  the	  amplified	  cell	  lines	  showed	  decreased	  proliferation	  in	  contrast	  to	  the	  non-­‐amplified	  cell	  lines	  that	  showed	  no	  difference	  in	  proliferation	  upon	  PHGDH	  knockdown	  indicating	  that	  the	  growth	  of	  the	  amplified	  cell	  lines	  is	  differentially	  sensitive	  to	  PHGDH	  knockdown	  (Fig	  3A,	  right).	  	  To	  verify	  that	  high	  expression	  leads	  to	  metabolic	  flux	  through	  the	  serine	  pathway,	  we	  measured	  the	  relative	  incorporation	  of	  13C	  serine	  from	  [U-­‐13C]	  glucose	  and	  found	  that	  each	  of	  the	  amplified	  cell	  lines	  had	  appreciable	  glycolytic	  flux	  into	  serine	  (Fig	  3B).	  	  One	  cell	  line	  that	  did	  not	  contain	  the	  amplification,	  Carney,	  had	  high	  expression	  of	  PHGDH	  and	  high	  flux	  into	  serine	  synthesis	  (Fig	  3A,B).	  	  Previous	  studies	  of	  oncogene	  addiction	  have	  shown	  that	  loss	  of	  cancer	  cell	  proliferation	  correlates	  with	  the	  presence	  of	  a	  genetic	  lesion	  and	  not	  with	  gene	  expression15,16.	  	  Consistent	  with	  these	  findings,	  it	  was	  observed	  that	  PHGDH	  knockdown	  had	  no	  effect	  on	  growth	  in	  Carney	  cells	  despite	  increased	  serine	  pathway	  flux	  (Fig	  3A).	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We	  then	  asked	  whether	  knockdown	  of	  PHGDH	  to	  levels	  that	  impair	  proliferation	  also	  affects	  metabolism.	  	  Metabolomics	  was	  carried	  out	  on	  SK-­‐Mel28	  cells	  using	  targeted	  LC/MS	  to	  profile	  metabolite	  levels	  with	  or	  without	  knockdown	  of	  PHGDH.	  	  Consistent	  with	  affecting	  the	  activity	  of	  glucose	  flux	  into	  serine	  metabolism,	  PHGDH	  knockdown	  reduced	  pSER	  levels	  in	  Sk-­‐Mel28	  cells	  (Fig	  3C)	  and	  globally	  altered	  metabolite	  levels	  including	  the	  levels	  of	  many	  intermediates	  in	  glycolysis	  (Fig	  3D,	  Supplementary	  Table	  S3).	  	  Increased	  levels	  of	  metabolites	  in	  glycolysis	  near	  the	  point	  of	  diversion	  into	  serine	  metabolism	  were	  observed	  (Fig	  3E)	  confirming	  that	  the	  level	  of	  PHGDH	  expression	  alters	  glucose	  metabolism	  in	  SkMel-­‐28	  cells	  by	  modulating	  the	  entry	  of	  glycolytic	  metabolites	  into	  serine	  metabolism.	  While	  copy	  number	  gain	  at	  the	  PHGDH	  genomic	  locus	  is	  one	  mechanism	  to	  divert	  flux	  into	  serine	  biosynthesis,	  other	  mechanisms	  to	  elevate	  PHGDH	  expression	  likely	  exist	  and	  may	  be	  important	  in	  specific	  cancer	  contexts.	  	  Recently,	  a	  study	  in	  breast	  cancer	  found	  enhanced	  high	  PHGDH	  mRNA	  expression	  was	  associated	  with	  poor	  prognosis	  in	  breast	  cancer17.	  	  Copy	  number	  gain	  was	  also	  found	  in	  breast	  cancer	  but	  at	  low	  frequency	  and	  in	  a	  broad	  peak	  region.	  	  To	  further	  investigate	  the	  role	  of	  PHGDH	  in	  breast	  cancer,	  we	  first	  carried	  out	  a	  bioinformatics	  analysis	  of	  multiple	  tumor	  microarray	  data	  sets	  in	  breast	  cancer	  and	  found	  strong	  associations	  (p	  <	  1e-­‐4)	  with	  several	  clinical	  parameters	  in	  breast	  cancer	  (Fig	  S4,	  Supplementary	  Table	  S4).	  	  These	  data	  suggest	  that	  PHGDH	  expression	  segregated	  with	  specific	  cancer	  subtypes.	  	  For	  validation,	  PHGDH	  protein	  expression	  in	  106	  human	  breast	  cancer	  tumor	  samples	  was	  assessed	  by	  IHC	  (Fig	  S5A)	  and	  correlated	  with	  mRNA	  expression	  (Fig	  S5B).	  	  It	  was	  found	  that	  high	  PHGDH	  expression	  (IHC	  score	  >	  1)	  was	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associated	  with	  distinct	  subtypes	  of	  breast	  cancer,	  as	  expression	  correlated	  with	  both	  triple-­‐negative18	  (p	  =	  0.002,	  Fisher’s	  exact,	  two	  tailed	  )	  and	  basal	  subtypes	  (p	  =	  0.004,	  Fisher’s	  exact,	  two	  tailed)	  (Fig	  S6).	  	  However,	  there	  was	  no	  association	  with	  general	  parameters	  such	  as	  metastasis	  as	  was	  previously	  reported17	  or	  with	  tumor	  size	  also	  suggesting	  that	  expression	  is	  subtype	  specific.	  	  Consistent	  with	  a	  reliance	  of	  a	  subset	  of	  breast	  cancers	  on	  PHGDH,	  protein	  expression	  was	  required	  for	  growth	  in	  a	  panel	  of	  three	  (BT-­‐20,	  SK-­‐BR-­‐3,	  MCF-­‐7)	  breast	  cancer	  cell	  lines	  (including	  the	  BT-­‐20	  cell	  line	  that	  carries	  amplification)	  to	  differing	  extents	  (Fig	  S7A).	  	  Furthermore,	  decreased	  PHGDH	  expression	  decreased	  pSer	  levels	  in	  PHGDH	  amplified	  BT-­‐20	  cells.	  	  In	  contrast,	  non-­‐tumorigenic	  breast	  epithelial	  cells	  (MCF-­‐10a)	  did	  not	  require	  PHGDH	  for	  growth	  (Fig	  S7A),	  did	  not	  exhibit	  alterations	  in	  glycolysis	  upon	  shRNA	  knockdown	  of	  PHGDH	  (Fig	  S7B)	  and	  exhibited	  no	  detectable	  labeling	  of	  pSER	  from	  glucose	  (Fig	  S7C).	  	  	  	  We	  therefore	  questioned	  whether	  ectopic	  expression	  of	  PHGDH	  would	  increase	  flux	  of	  glucose	  to	  serine	  and	  have	  any	  phenotypic	  consequences.	  	  MCF-­‐10a	  cells	  are	  non-­‐tumorigenic	  and,	  when	  grown	  in	  reconstituted	  basement	  membrane	  (™Matrigel)	  form	  structures	  resembling	  many	  features	  of	  mammary	  acini.	  	  These	  acini-­‐like	  structures	  are	  polarized	  and	  characterized	  by	  a	  hollow	  lumen	  due	  to	  selective	  apoptosis	  of	  the	  inner,	  matrix-­‐deprived	  cells.	  	  This	  model	  has	  been	  used	  to	  monitor	  alterations	  in	  growth	  arrest,	  polarization,	  invasive	  behavior	  and	  other	  disruptions	  of	  normal	  morphogenesis	  that	  resemble	  changes	  associated	  with	  different	  stages	  of	  tumor	  formation19.	  	  PHGDH	  was	  expressed	  in	  MCF-­‐10a	  cells	  using	  a	  tetracycline-­‐inducible	  expression	  vector	  and	  treatment	  of	  the	  engineered	  MCF-­‐
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10A	  cells	  with	  increasing	  concentrations	  of	  doxycycline	  induced	  expression	  of	  PHGDH	  (Fig	  4A).	  	  pSER	  levels	  were	  elevated	  to	  detectable	  levels	  in	  cells	  treated	  with	  1µg/ml	  doxycycline	  indicating	  an	  increase	  in	  pathway	  activity	  (Fig	  4B)	  that	  was	  confirmed	  with	  GC/MS	  that	  measured	  an	  increase	  in	  Serine	  and	  Glycine	  synthesis	  (Fig	  S7D).	  	  	  We	  seeded	  PHGDH-­‐expressing	  MCF-­‐10A	  cells	  in	  ™Matrigel	  reconstituted	  basement	  membrane	  and	  monitored	  the	  structures	  at	  increasing	  doses	  of	  doxycycline	  using	  confocal	  microscopy	  and	  immunofluorescence	  staining	  of	  nuclei	  (DAPI)	  and	  extracellular	  matrix	  (laminin-­‐5)	  (Fig	  4C).	  	  In	  the	  absence	  of	  doxycycline,	  MCF-­‐10A	  cells	  formed	  hollow,	  acini-­‐like	  structures	  as	  previously	  reported20(Fig	  4C).	  	  In	  contrast,	  PHGDH-­‐expressing	  cells	  formed	  disorganized	  structures	  lacking	  a	  lumen	  (Fig	  4C).	  The	  PHGDH-­‐expressing	  cells	  also	  exhibited	  large,	  abnormal	  nuclear	  morphologies,	  failed	  to	  orient	  in	  a	  uniform	  fashion	  adjacent	  to	  the	  basal	  acinar	  membrane,	  and	  displayed	  enhanced	  proliferation	  (Fig	  4D).	  	  The	  majority	  of	  the	  control	  acini	  were	  either	  clear	  or	  mostly	  clear,	  whereas	  PHGDH	  expression	  dramatically	  increased	  the	  percentage	  of	  acini	  that	  scored	  as	  mostly	  filled	  or	  filled	  in	  a	  dose	  dependent	  manner	  (Fig.	  4E).	  	  An	  activity-­‐compromised	  mutant	  PHGDH	  (V490M)21	  showed	  decreased	  luminal	  filling	  (Fig	  4F	  and	  S7E).	  	  In	  addition,	  MCF-­‐10A	  acini	  with	  ectopic	  expression	  of	  wild-­‐type	  but	  not	  mutant	  PHGDH	  commonly	  displayed	  mislocalization	  of	  the	  golgi	  apparatus	  indicating	  loss	  of	  apical	  polarity	  (Fig.	  4F).	  	  These	  results	  indicate	  that	  PHGDH	  expression	  alters	  glucose	  metabolism,	  disrupts	  luminal	  organization	  and	  polarity	  and	  preserves	  the	  viability	  of	  the	  inner,	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matrix-­‐deprived	  cells	  to	  survive	  in	  an	  anchorage-­‐independent	  fashion.	  	  Importantly,	  these	  phenotypes	  depend	  on	  the	  catalytic	  activity	  of	  PHGDH.	  	  	  Although	  numerous	  studies	  have	  correlated	  oncogenesis	  with	  changes	  in	  cell	  metabolism,	  only	  a	  few	  studies	  have	  suggested	  that	  genetic	  aberrations	  in	  metabolic	  genes	  are	  capable	  of	  driving	  tumorigenesis22.	  	  Oncogenic	  mutations	  in	  the	  metabolic	  enzyme	  isocitrate	  dehydrogenase	  have	  recently	  been	  described23.	  	  These	  mutations	  result	  in	  production	  of	  a	  metabolite	  not	  normally	  produced	  in	  cells24,	  suggesting	  that	  altered	  metabolic	  flux	  may	  promote	  oncogenesis.	  	  Here	  we	  show	  that	  PHGDH,	  a	  focus	  of	  recurrent	  genomic	  amplification,	  diverts	  glycolysis	  into	  a	  specific	  biosynthetic	  pathway	  and	  that	  this	  change	  in	  metabolism	  can	  be	  selected	  for	  in	  the	  development	  of	  human	  cancer.	  	  	   The	  diversion	  of	  glycolytic	  flux	  into	  de	  novo	  serine	  biosynthesis	  has	  a	  multitude	  of	  biological	  consequences.	  	  Metabolic	  pathways	  downstream	  of	  serine	  metabolism	  contribute	  to	  growth-­‐promoting	  biosynthesis	  and	  metabolic	  signaling	  functions	  from	  the	  folate	  pool,	  amino	  acid,	  and	  lipid	  intermediates,	  and	  redox	  regulation20,25-­‐27.	  	  In	  addition,	  the	  process	  of	  diverting	  fluxes	  from	  3PG	  out	  of	  glycolysis	  confers	  several	  advantages	  for	  cell	  growth.	  	  These	  include	  limiting	  ATP	  production,	  direct	  alterations	  in	  cellular	  redox	  status	  from	  the	  oxidation	  of	  3PG,	  and	  the	  generation	  of	  αKG	  from	  glutamate,	  all	  of	  which	  are	  reported	  to	  benefit	  cell	  growth	  through	  multiple	  mechanisms28-­‐30.	  	  Since	  the	  consequences	  of	  PHGDH	  amplification	  and	  increased	  glucose	  flux	  into	  serine	  metabolism	  are	  numerous,	  multi-­‐factorial,	  and	  comparable	  to	  the	  number	  of	  processes	  affected	  by	  classic	  oncogenes	  such	  as	  KRAS,	  it	  is	  not	  likely	  that	  a	  single	  biological	  mechanism	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contributes	  to	  cell	  transformation	  downstream	  of	  PHGDH	  amplification.	  	  Nevertheless,	  the	  observation	  that	  a	  genetic	  lesion	  can	  function	  to	  directly	  alter	  metabolic	  flux	  out	  of	  glycolysis	  provides	  multiple	  avenues	  for	  further	  inquiry	  and	  demonstrates	  that	  alterations	  in	  metabolism	  beyond	  increased	  lactate	  production	  are	  important	  events	  in	  the	  development	  of	  cancer.	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Figure	  Captions	  	  
	  
Figure	  1	  	  -­‐	  Observation	  of	  glycolytic	  metabolism	  being	  diverted	  into	  serine	  and	  
glycine	  metabolism	  a.)	  Spectral	  bins	  of	  [1H,	  13C]	  HSQC	  NMR	  of	  [U-­‐13C]	  glucose-­‐labeled	  cell	  extracts	  sorted	  by	  intensity	  in	  standard	  units	  (z-­‐score).	  	  Four	  highest	  intensity	  peaks	  correspond	  to	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metabolites	  lactate,	  alanine,	  and	  glycine	  respectively.	  	  b.)	  Relative	  intensity	  13C	  glycine	  peak	  normalized	  to	  an	  internal	  50mM	  DSS	  standard	  in	  HEK293T,	  H1299,	  and	  MCF-­‐10a	  cells.	  	  c.)	  Schematic	  of	  diversion	  of	  glucose	  metabolism	  into	  serine	  and	  glycine	  metabolism	  at	  the	  3-­‐phosphoglycerate	  (3PG)	  step	  through	  PHGDH.	  	  d.)	  Time	  (0,	  5,	  10,	  15,	  30	  minutes)	  courses	  of	  U-­‐13C	  labeling	  intensities	  of	  thirteen	  metabolites	  from	  [U-­‐13C]	  glucose	  labeling	  experiments	  measured	  with	  targeted	  LC/MS	  relative	  to	  baseline	  level	  at	  time	  zero.	  	  e.)	  Comparison	  of	  3-­‐phosphoserine	  (pSER)	  and	  phosphoenolpyruvate	  (PEP)	  labeling	  kinetics	  	  of	  [U-­‐13C]	  glucose	  relative	  to	  baseline	  level	  at	  time	  zero	  with	  targeted	  LC/MS.	  	  f.)	  Relative	  glucose	  flux	  into	  serine	  biosynthesis	  measured	  by	  steady-­‐state	  labeling	  of	  [U-­‐13C]	  glucose	  into	  serine	  with	  targeted	  LC/MS.	  	  The	  fraction	  of	  labeled	  to	  unlabeled	  glucose-­‐derived	  metabolites	  13C/(12C+13C)	  ion	  intensities	  (glucose	  incorporation)	  is	  plotted	  for	  12	  metabolites.	  	  Serine	  is	  compared	  with	  respect	  to	  the	  glucose-­‐labeled	  fraction	  of	  downstream	  nucleotides	  and	  other	  nucleotide	  precursors.	  	  g.)	  Relative	  protein	  levels	  (as	  determined	  by	  western	  blot	  analysis)	  of	  PHGDH	  in	  HEK293T,	  H1299,	  and	  MCF-­‐10a	  cells	  with	  a	  Beta-­‐actin	  (Actin)	  loading	  control	  shown	  below	  the	  PHGDH	  band.	  	  Quantitation	  relative	  to	  the	  levels	  in	  MCF-­‐10a	  cells	  of	  the	  total	  intensity	  of	  the	  PHGDH	  band	  relative	  to	  the	  Actin	  band	  is	  shown	  above.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  2	  	  -­‐	  PHGDH	  amplification	  in	  human	  cancers	  and	  requirement	  for	  
proliferation	  a.)	  Global	  survey	  of	  PHGDH	  copy	  number	  intensity	  across	  3131	  cancers.	  	  (left)	  Plot	  significance	  of	  amplifications	  (FDR	  q-­‐value)	  along	  chromosome	  1p	  (from	  Telomere	  to	  Centromere)	  across	  3131	  samples.	  	  Candidate	  oncogenes	  (TP73,	  MYCL1,	  and	  JUN)	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in	  three	  peak	  regions	  and	  corresponding	  FDR	  q-­‐values	  are	  shown.	  	  FDR	  q-­‐value	  of	  PHGDH	  is	  shown	  in	  the	  fourth	  peak	  region.	  	  (middle)	  Copy	  number	  intensity	  along	  chromosome	  1p	  of	  150	  cancers	  containing	  highest	  intensity	  of	  PHGDH	  amplification	  that	  illustrates	  the	  localized	  intensity	  near	  the	  region	  of	  PHGDH.	  	  Blue	  indicates	  deleted	  region,	  white	  indicates	  neutral	  region	  and	  red	  indicates	  amplified	  region.	  (right)	  Magnification	  of	  4MB	  region	  containing	  PHGDH.	  	  Solid	  line	  indicates	  chromosome	  position	  of	  PHGDH	  coding	  region.	  Ratios	  of	  ion	  intensities	  (fold	  change)	  are	  plotted.	  	  b.)	  Relative	  cell	  numbers	  of	  T.T.	  cells	  upon	  knockdown	  with	  respect	  to	  shGFP	  of	  GFP,	  PHGDH,	  PSAT,	  and	  PSPH.	  	  Error	  bars	  represent	  the	  standard	  deviation	  of	  n	  =3	  independent	  measurements.	  	  (below)	  Interphase	  FISH	  analysis	  showing	  PHGDH	  copy	  number	  gain	  in	  T.T.	  cells.	  	  The	  green	  probe	  maps	  to	  1p12	  and	  includes	  the	  PHGDH	  coding	  sequence.	  The	  red	  probe	  maps	  to	  the	  pericentromeric	  region	  of	  chromosome1	  (1p11.2-­‐q11.1).	  	  (below)	  Relative	  protein	  levels	  of	  PHGDH,	  PSAT,	  and	  PSPH	  (as	  determined	  by	  western	  blot	  analysis)	  in	  T.T.	  cells	  following	  expression	  of	  an	  shRNA	  against	  GFP	  (shGFP),	  PHGDH	  (shPHGDH),	  PSAT	  (shPSAT),	  and	  PSPH	  (shPSPH)	  respectively.	  	  c.)	  PHGDH	  protein	  expression	  and	  copy	  number	  gain	  in	  three	  representative	  human	  tissue	  samples.	  	  (upper)	  PHGDH	  expression	  was	  assessed	  in	  tumor	  samples	  using	  Immunohistochemistry	  (IHC).	  	  Nuclei	  are	  shown	  in	  blue	  (hematoxylin)	  and	  PHGDH	  antibody	  staining	  is	  shown	  in	  brown	  (3-­‐3’-­‐Diaminobenzidine	  [DAB]).	  	  (lower)	  panels	  contain	  interphase	  FISH	  analysis	  that	  was	  carried	  out	  as	  in	  Fig	  2B	  in	  matched	  samples	  to	  assess	  copy	  number	  (green)	  relative	  to	  the	  pericentromeric	  probe	  (red).	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Figure	  3	  –	  Growth	  dependence	  of	  PHGDH	  expression	  and	  altered	  serine	  
metabolism	  in	  PHGDH-­‐amplified	  human	  melanoma	  cells	  a.)	  Growth	  assay	  of	  stable	  cell	  lines	  containing	  shGFP	  or	  shPHGDH	  in	  five	  human	  melanoma	  cell	  line.	  	  Three	  (WM266-­‐3,	  Malme-­‐3M	  (Malme),	  and	  SkMel-­‐28	  (Sk28)	  contain	  1p12	  copy	  number	  gain	  and	  two	  (GAK,	  Carney)	  other	  melanoma	  cell	  lines	  are	  considered.	  	  (left)	  Western	  blot	  analysis	  of	  protein	  levels	  of	  PHGDH	  and	  corresponding	  protein	  levels	  of	  Actin	  shown	  as	  a	  loading	  control.	  	  (right)	  Cell	  numbers	  for	  shGFP	  and	  shPHGDH	  normalized	  to	  shGFP	  are	  plotted	  for	  each	  cell	  line.	  	  Error	  bars	  were	  obtained	  from	  the	  standard	  deviation	  of	  n	  =3	  independent	  measurements.	  	  b.)	  Relative	  amount	  of	  glucose	  flux	  into	  serine	  biosynthesis	  measured	  by	  steady-­‐state	  labeling	  of	  [U-­‐13C]	  glucose	  into	  serine	  with	  targeted	  LC/MS.	  	  The	  fraction	  of	  labeled	  to	  unlabeled	  glucose-­‐derived	  serine	  to	  total	  serine,	  
13C/12C+13C,	  (serine	  incorporation)	  is	  measured	  in	  each	  of	  the	  five	  cell	  lines.	  	  Error	  bars	  were	  obtained	  from	  the	  standard	  deviation	  of	  n	  =3	  independent	  measurements.	  	  c.)	  Relative	  ion	  intensities	  of	  3-­‐phosphoserine	  (pSer)	  in	  control	  (shGFP)	  and	  knockdown	  (shPHGDH)	  cells	  normalized	  to	  intensity	  in	  knockdown	  shGFP	  cells	  (pSer/shGFP).	  	  Error	  bars	  were	  obtained	  from	  the	  standard	  deviation	  of	  n	  =3	  independent	  measurements.	  	  d.)	  Scatter	  plot	  of	  the	  ratio	  of	  intensities	  (fold	  change),	  versus	  p	  value	  (student’s	  t-­‐test)	  of	  shPHGDH	  relative	  to	  shGFP	  in	  Sk-­‐Mel28	  cells.	  	  e.)	  Ratio	  of	  intensities	  (fold	  change)	  of	  glycolytic	  intermediates	  upon	  PHGDH	  knockdown	  (shPHGDH)	  relative	  to	  (shGFP)	  in	  Sk-­‐Mel28	  cells.	  	  Error	  bars	  were	  obtained	  from	  propagation	  of	  error	  of	  the	  standard	  deviation	  from	  three	  independent	  measurements.	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Figure	  4	  –	  Enhanced	  PHGDH	  expression	  in	  human	  breast	  cancer	  and	  ectopic	  
expression	  of	  PHGDH	  in	  ductal	  morphogenesis.	  	  a.)	  	  Protein	  expression	  of	  PHGDH	  by	  western	  blot	  analysis	  with	  Actin	  as	  loading	  for	  three	  concentration	  of	  Doxycycline	  	  	  (0µg/ml,	  1µg/ml,	  2µg/ml).	  	  b.)	  	  pSER	  integrated	  intensities	  in	  –Dox	  (0µg/ml)	  and	  +Dox	  (1µg/ml).	  	  c.)	  Confocal	  images	  of	  DAPI	  (Blue),	  Laminin	  5	  (Green).	  	  Representative	  images	  from	  four	  acini	  from	  MCF-­‐10A	  cells	  expressing	  doxycyline-­‐inducible	  PHGDH	  without	  doxycycline	  (-­‐Dox)	  or	  1	  μg/ml	  doxycyline	  (+Dox).	  	  d.)	  Enhanced	  proliferation	  in	  the	  interior	  of	  PHGDH-­‐expressing	  acini.	  	  Representative	  images	  from	  acini	  from	  MCF-­‐10A	  cells	  expressing	  doxycyline-­‐inducible	  PHGDH	  without	  doxycycline	  (No	  Dox)	  or	  1	  μg/ml	  doxycyline	  (1	  μg/ml	  Dox).	  	  Confocal	  images	  of	  MCF-­‐10A	  cells	  under	  the	  same	  conditions	  as	  in	  4C	  with	  DAPI	  (Blue)	  and	  the	  proliferation	  marker	  Ki67	  (Red).	  	  e.)	  Quantification	  of	  acinar	  filling	  for	  0	  μg/ml,	  1	  μg/ml,	  and	  2μg/ml	  Dox.	  	  Each	  acini	  was	  scored	  as	  filled,	  mostly	  filled,	  mostly	  clear,	  and	  clear.	  	  These	  data	  are	  representative	  of	  multiple	  independent	  measurements.	  	  f.)	  Loss	  of	  apical	  polarity	  in	  PHGDH-­‐expressing	  cells.	  	  Confocal	  images	  of	  MCF-­‐10A	  cells	  under	  the	  same	  conditions	  as	  in	  4C	  with	  DAPI	  (Blue)	  and	  Golgi	  Apparatus	  (Green).	  	  Solid,	  white	  arrows	  indicate	  cells	  displaying	  oriented	  golgi	  apparatus.	  	  Dashed,	  yellow	  arrows	  indicate	  cells	  exhibiting	  loss	  of	  polarity.	  	  Acini	  with	  ectopic	  expression	  of	  wild	  type,	  but	  not	  mutant	  V490M,	  PHGDH	  commonly	  display	  mislocalized	  golgi	  apparatus,	  indicative	  of	  a	  lack	  of	  cell	  polarity.	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Supplementary	  Figure	  1	  -­‐	  Time	  course	  of	  glucose	  flux	  into	  de	  novo	  serine	  
biosynthesis	  	  
	  a.)	  	  Labeling	  of	  [U-­‐13C]	  L-­‐serine	  in	  HEK293T	  cells	  after	  0,5,10,15	  and	  30	  minutes	  of	  [U-­‐13C]	  glucose	  media	  replacement	  quantified	  by	  LC/MS.	  	  Ratio	  of	  13C	  L-­‐serine	  to	  13C	  L-­‐serine	  at	  time	  zero	  is	  plotted.	  	  Serine	  signal	  appears	  between	  5	  and	  10	  minutes.	  	  b.)	  GC/MS	  measurement	  of	  relative	  incorporation	  of	  [α-­‐15N]	  Glutamine	  into	  amino	  acids	  in	  HEK293T	  cells.	  	  Pool	  sizes	  of	  relative	  incorporation	  of	  amino	  acids	  are	  shown	  in	  a	  pie	  chart.	  	  	  	  	  
	  
Supplementary	  Figure	  2	  -­‐	  PHGDH	  copy	  number	  gain	  in	  Melanoma	  
	  150	  Melanoma	  samples	  sorted	  by	  intensity	  at	  the	  PHGDH	  genomic	  locus	  at	  1p12.	  	  39%	  contain	  copy	  number	  gain	  exhibiting	  the	  highest	  frequency	  of	  occurrence	  in	  cancer	  subtypes.	  	  
	  
Supplementary	  Figure	  3	  -­‐	  PHGDH	  protein	  expression	  in	  human	  melanoma	  	  
	  a.)	  	  Immunohistochemistry	  (IHC)	  of	  n	  =	  381	  samples	  human	  tissue	  samples	  in	  a	  melanoma	  collection.	  	  Samples	  were	  scored	  from	  0	  (no	  expression)	  to	  3	  (high	  expression)	  and	  representative	  images	  are	  shown.	  	  Nuclei	  are	  shown	  in	  blue	  (hematoxylin)	  and	  PHGDH	  antibody	  is	  shown	  in	  brown	  (3-­‐3’-­‐Diaminobenzidine	  [DAB]).	  	  b.)	  	  Statistics	  of	  PHGDH	  expression	  according	  to	  scoring	  scheme	  in	  a.).	  	  Number	  of	  samples	  N	  that	  stain	  for	  each	  score	  and	  percentage	  values	  %	  are	  shown.	  	  	  c.)	  	  Representative	  image	  of	  interphase	  FISH	  analysis	  showing	  disomy	  of	  PHGDH	  (green)	  and	  pericentromeric	  probe	  (red)	  in	  a	  representative	  sample	  from	  the	  tissue	  microarray.	  	  	  	  	  	  	  	  	  




Associations	  of	  PHGDH	  expression	  with	  clinical	  parameters	  and	  prognosis	  in	  human	  breast	  cancer	  tumor	  microarray	  data	  sets.	  	  Test	  statistics	  are	  based	  on	  centroids	  and	  references	  are	  described	  in	  supplementary	  table	  4.	  	  	  	  	  
	  
Supplementary	  Figure	  5	  -­‐	  Analysis	  of	  PHGDH	  protein	  expression	  in	  human	  
breast	  cancer	  	  	  a.)	  IHC	  staining	  of	  a	  set	  of	  n	  =	  106	  human	  breast	  tumors.	  	  PHGDH	  is	  shown	  in	  brown	  (DAB)	  and	  nuclei	  are	  blue	  (Hematoxylin).	  	  Representative	  images	  from	  expression	  scores	  ranging	  from	  0	  (no	  expression)	  to	  3	  (high	  expression)	  are	  shown.	  	  b.)	  Average	  mRNA	  expression	  for	  each	  IHC	  expression	  score.	  	  
	  
Supplementary	  Figure	  6	  -­‐	  Association	  of	  PHGDH	  protein	  expression	  in	  human	  
breast	  cancer	  with	  clinical	  parameters	  and	  breast	  cancer	  subtypes	  
	  Overlay	  of	  PHGDH	  expression	  score	  (0	  -­‐	  green,	  1	  -­‐	  yellow,	  2	  -­‐	  orange,	  and	  3	  -­‐	  red)	  with	  previously	  defined	  clinical	  parameters.	  	  Color	  correspondence	  of	  each	  clinical	  parameter	  is	  shown	  in	  the	  legend.	  	  	  	  
Supplementary	  Figure	  7	  -­‐	  Characterization	  of	  metabolism	  and	  acinar	  
morphogenesis	  in	  MCF-­‐10a	  cells	  





PHGDH	  cloning	  	  Human	  PHGDH	  cDNA	  fragment	  was	  isolated	  with	  EcoRV	  and	  NotI	  from	  
PHGDH/pSport6	  (Openbiosystems	  MHS1010-­‐73507),	  and	  cloned	  into	  the	  blunted	  BamHI	  and	  NotI	  sites	  of	  a	  pLvx-­‐Tight-­‐Puro	  (Clontech)	  tetracycline	  inducible	  vector.	  	  
PHGDH	  RNA	  interference	  
	  shRNA	  hairpins	  in	  lentiviral	  vector	  plasmids	  pLKO.1	  were	  purchased	  from	  open	  biosystems	  (http://www.openbiosystems.com).	  	  RNA	  interference	  was	  obtained	  using	  PHGDH	  targeting	  sequences	  (shPHGDH)	  (TRCN0000028548)	  CCGGAGGTGATAACACAGGGAACATCTCGAGATGTTCCCTGTGTTATCACCTTTTTT	  and	  (TRCN0000028545),	  CCGGCTTAGCAAAGAGGAGCTGATACTCGAGTATCAGCTCCTCTTTGCTAAGTTTTT.	  	  	  A	  control	  hairpin	  in	  pLKO.1	  vector	  was	  used	  targeting	  GFP	  (shGFP).	  	  HEK293T	  cells	  were	  transfected	  with	  pLKO.1	  vectors	  and	  lenti-­‐viral	  packaging	  vectors.	  	  All	  cell	  lines	  were	  infected	  using	  standard	  protocols.	  	  Selection	  under	  2µg/ml	  puromycin	  was	  carried	  out	  at	  least	  two	  days	  prior	  to	  experiments.	  	  
Cell	  lysis,	  western	  blot,	  and	  Immunohistochemistry	  analysis	  	  Exponentially	  growing	  cells	  were	  first	  washed	  with	  cold	  PBS	  and	  lysed	  with	  RIPA	  buffer	  (10	  mM	  Tris	  (7.5),	  150	  mM	  NaCl,	  1%	  Nonidet	  P-­‐40,	  1%	  Deoxycholic	  acid,	  0.1%	  SDS,	  and	  4	  μg/mL	  each	  of	  pepstatin,	  leupeptin,	  4-­‐(2-­‐Aminoethyl)	  benzenesulfonyl	  fluoride	  hydrochloride)	  and	  aprotinin,	  a	  phosphatase	  inhibitor	  cocktail	  (ThermoScientific)	  and	  1mM	  DTT.	  	  Lysates	  were	  centrifuged	  at	  14,000	  rpm	  at	  4°C	  for	  30	  minutes	  and	  supernatant	  retained.	  	  Protein	  concentration	  was	  determined	  with	  Bradford	  assay	  (BioRad).	  	  Mouse	  monoclonal	  PHGDH	  antibody	  was	  purchased	  from	  Santa	  Cruz	  (sc-­‐100317)	  and	  mouse	  monoclonal	  beta	  actin	  (abCam	  ab8226)	  was	  used	  as	  a	  loading	  control.	  	  Both	  mouse	  anti-­‐PSAT	  antibody	  (Novus)	  and	  rabbit	  anti-­‐PSPH	  antibody	  (Sigma)	  were	  used	  at	  dilutions	  of	  1:1000.	  	  PHGDH	  antibody	  was	  used	  at	  1:500	  dilution	  and	  incubated	  at	  4°C	  overnight	  with	  5%	  dry	  milk	  in	  Tris-­‐buffered	  saline	  (0.05%	  Tween).	  	  Beta	  actin	  antibody	  was	  used	  at	  a	  1:10000	  dilution.	  	  Secondary	  antibodies	  conjugated	  to	  Horseradish	  Peroxidase	  were	  used	  at	  1:10000	  dilution.	  	  Western	  blots	  were	  developed	  using	  chemiluminescence.	  	  Quantitation	  was	  carried	  out	  using	  ImageJ	  software.	  	  For	  Immunohistochemistry,	  mouse	  monoclonal	  PHGDH	  antibody	  was	  purchased	  from	  Santa	  Cruz	  (sc-­‐100317)	  and	  used	  at	  1:15	  dilution.	  	  Antibody	  specificity	  was	  first	  validated	  using	  paraffin-­‐embedded	  cell	  blocks	  obtained	  from	  shGFP	  and	  shPHGDH	  expressing	  cell	  lines.	  	  All	  IHC	  staining	  was	  carried	  out	  using	  a	  Dako	  Envision	  (K4006)	  IHC	  kit	  with	  hematoxylin	  nuclear	  counterstain	  and	  3-­‐3’-­‐Diaminobenzidine	  [DAB]	  antibody	  stain.	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Cell	  culture	  	  	  The	  T.T	  cell	  line	  was	  a	  gift	  from	  Anil	  Rustgi.	  	  All	  human	  melanoma	  cell	  lines	  were	  obtained	  as	  gifts	  from	  Lynda	  Chin.	  	  All	  other	  cell	  lines	  were	  obtained	  from	  ATCC.	  	  HEK293T,	  SkBr3,	  MCF7,	  and	  T.T.	  cells	  were	  grown	  DMEM	  (Mediatech),	  10%	  FBS,	  and	  antibiotics	  (Penicilin/Streptomycin,	  Invitrogen).	  	  H1299	  cells	  were	  grown	  in	  RPMI	  (Mediatech),	  10%	  FBS,	  and	  antibiotics.	  	  All	  human	  melanoma	  cell	  lines	  were	  cultured	  as	  previously	  in	  RPMI	  (Mediatech)	  with	  10%	  FBS	  and	  antibiotics.	  	  BT20	  cells	  were	  cultured	  in	  MEM	  (Mediatech),	  10%	  FBS,	  and	  antibiotics.	  	  Early	  passage	  MCF-­‐10a	  cells	  were	  cultured	  according	  to	  a	  protocol	  previously	  established	  using	  DMEM/F12(Mediatech),	  5%	  Horse	  Serum,	  antibiotics	  supplemented	  with	  Insulin,	  EGF,	  Hydrocortisone,	  and	  Cholera	  Toxin31.	  	  Growth	  media	  contained	  the	  standard	  concentrations	  of	  glutamine	  but	  was	  not	  supplemented	  with	  additional	  glutamine.	  	  	  	  	  
NMR Sample Preparation, spectroscopy,	  data	  analysis	   108	   exponentially	   growing	   HEK293T,	   H1299	   and	   MCF-­‐10a	   cells	   growing	   in	   basal	  growth	  media	  with	  dialyzed	  serum	  were	  harvested	  and	  metabolites	  were	  extracted	  in	  50mL	  of	  80%	  Methanol	  (v/v)	  at	  dry	  ice	  temperatures.	  	  Cells	  were	  incubated	  with	  [U13C]-­‐glucose	  (Cambridge	   Isotope	  Laboratories)	  replaced	  at	  25mM	  and	   incubated	  24	   hrs	   prior	   to	   harvesting.	   	   Fresh	   media	   were	   added	   2	   hours	   prior	   to	   the	  experiment.	   	   Lysates	   were	   centrifuged	   at	   10,000g	   for	   30	   minutes	   at	   4°C	   and	  supernatant	  was	  stored.	  	  Methanol	  was	  first	  evaporated	  at	  cold	  temperature	  under	  vacuum	   with	   rotational	   evaporation	   and	   samples	   were	   subsequently	   lyophilized.	  Samples	   were	   prepared	   for	   NMR	   spectroscopy	   by	   resuspending	   the	   lyophilized	  material	  in	  700	  µl	  of	  sample	  buffer,	  containing	  50mM	  NaPO4	  (pH=7.0)	  and	  2mM	  DSS	  (as	   an	   internal	   standard	   and	   chemical	   shift	   reference).	   The	   samples	   were	  immediately	   transferred	   into	   5mm,	   7’’	   NMR	   tubes	   (Wilmad	   lab	   glass)	   for	   data	  acquisition.	  	  All	   NMR	   spectra	   were	   acquired	   on	   a	   Bruker	   500MHz	   spectrometer	   (Bruker,	   Inc.,	  Billerica,	   MA.)	   using	   a	   5mm	   triple	   resonance	   (H,	   C,	   N)	   Cryoprobe.	   The	   sample	  temperature	  was	  25	  degrees	  centigrade	  for	  all	  samples.	   	  Two-­‐dimensional	  1H-­‐13C	  HSQC	  spectra	  with	  sensitivity	  enhancement	  were	  acquired	  with	  spectral	  widths	  of	  12000	   and	   9048Hz	   in	   the	   direct	   and	   indirect	   dimensions,	   respectively.	   1024	  complex	  data	  points	  were	  acquired	  in	  the	  direct	  dimension,	  and	  256	  complex	  points	  were	  acquired	  in	  the	  indirect	  dimension	  in	  a	  linear	  fashion,	  with	  a	  subsequent	  256	  complex	  points	  being	  acquired	  with	  a	  non-­‐uniform	  random	  sampling	  scheme.	  The	  total	  acquisition	   time	   for	   the	   indirect	  dimension	  was	  113	  milliseconds.	  64	  dummy	  scans	  were	   collected	  prior	   to	   the	   first	   increment,	   and	  16	   scans	  were	  acquired	  per	  increment.	  	  The	  resulting	  HSQC	  spectra	  were	  processed	  using	  NMRpipe.	  	  A	  zero	  order	  phase	  correction	  in	  the	  directly	  detected	  dimension	  was	  used.	  	  Spectra	  were	  then	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extracted	  in	  ascii	  format	  and	  peaks	  from	  0-­‐10	  ppm	  in	  the	  proton	  dimension	  and	  20-­‐160	  ppm	  in	  the	  carbon	  dimension	  were	  considered.	  	  This	  resulted	  in	  1704	  data	  points	  in	  the	  direct	  dimension	  and	  423	  data	  points	  in	  the	  indirectly	  detected	  dimension.	  	  The	  resulting	  intensities	  at	  each	  data	  point	  were	  then	  binned	  using	  an	  eight-­‐fold	  reduction	  in	  the	  proton	  dimension	  and	  a	  two-­‐fold	  reduction	  in	  the	  carbon	  dimension.	  	  The	  intensities	  at	  each	  point	  in	  the	  resulting	  213	  x	  206	  lattice	  were	  then	  computed	  and	  a	  baseline	  value	  of	  5e6	  was	  defined	  that	  corresponded	  to	  a	  value	  above	  the	  signal	  to	  noise	  level	  and	  each	  bin	  exhibiting	  sum	  intensity	  less	  than	  that	  of	  the	  baseline	  was	  set	  to	  the	  baseline.	  	  Bins	  in	  the	  region	  of	  the	  spectra	  containing	  the	  water	  line	  (4.60	  –	  4.75	  ppm)	  were	  omitted.	  	  The	  resulting	  bins	  that	  displayed	  at	  least	  a	  two-­‐fold	  increase	  in	  the	  intensity	  relative	  to	  the	  noise	  level	  were	  considered.	  	  Individual	  metabolite	  assignments	  were	  carried	  out	  using	  the	  Human	  Metabolome	  Database	  (HMDB).	  	  Computer	  code	  was	  written	  in	  the	  PERL	  interpreting	  language.	  	  Zscores	  (i.e.	  intensities	  in	  standard	  units)	  were	  computed	  in	  Matlab.	  13C	  Glycine	  peaks	  were	  integrated	  separately	  using	  the	  Sparky	  software	  package	  (www.cgl.ucsf.edu/home/sparky/).	  	  Peak	  intensities	  were	  computed	  using	  gaussian	  integration	  and	  error	  bars	  obtained	  from	  RMS	  residuals.	  	  	  	  	  
Targeted	  Liquid-­‐Chromatography	  Mass	  Spectrometry	  (LC/MS)	  
	  106	  cells	  exponentially	  growing	  in	  basal	  media	  with	  dialyzed	  serum	  were	  harvested	  in	  3mL	  80%	  v/v	  methanol	  at	  dry	  ice	  temperatures.	  	  Fresh	  media	  was	  added	  24	  hours	  and	  2	  hours	  prior	  to	  the	  experiment.	  	  Insoluble	  material	  in	  lysates	  was	  centrifuged	  at	  4000RPM	  for	  15	  minutes	  and	  resulting	  supernatant	  was	  evaporated	  using	  a	  refrigerated	  speed-­‐vac.	  	  Samples	  were	  resuspended	  using	  20µL	  HPLC	  grade	  water	  for	  mass	  spectrometry.	  	  10μL	  were	  injected	  and	  analyzed	  using	  a	  5500	  QTRAP	  triple	  quadrupole	  mass	  spectrometer	  (AB/MDS	  Sciex)	  coupled	  to	  a	  Prominence	  UFLC	  HPLC	  system	  (Shimadzu)	  via	  selected	  reaction	  monitoring	  (SRM)	  of	  a	  total	  of	  249	  endogenous	  water	  soluble	  metabolites	  for	  analyses	  of	  samples.	  	  Some	  metabolites	  were	  targeted	  in	  both	  positive	  and	  negative	  ion	  mode	  for	  a	  total	  of	  298	  SRM	  transitions.	  	  ESI	  voltage	  was	  5000V	  in	  positive	  ion	  mode	  and	  –4500V	  in	  negative	  ion	  mode.	  	  The	  dwell	  time	  was	  5	  ms	  per	  SRM	  transition	  and	  the	  total	  cycle	  time	  was	  2.09	  seconds.	  	  Samples	  were	  delivered	  to	  the	  MS	  via	  normal	  phase	  chromatography	  using	  a	  2.0	  mm	  i.d	  x	  15	  cm	  Luna	  NH2	  HILIC	  column	  (Phenomenex)	  at	  285	  μL/min.	  	  Gradients	  were	  run	  starting	  from	  85%	  buffer	  B	  (HPLC	  grade	  acetonitrile)	  to	  42%	  B	  from	  0-­‐5	  minutes;	  42%	  B	  to	  0%	  B	  from	  5-­‐16	  minutes;	  0%	  B	  was	  held	  from	  16-­‐24	  minutes;	  0%	  B	  to	  85%	  B	  from	  24-­‐25	  minutes;	  85%	  B	  was	  held	  for	  7	  minutes	  to	  re-­‐equilibrate	  the	  column.	  	  Buffer	  A	  was	  comprised	  of	  20	  mM	  ammonium	  hydroxide/20	  mM	  ammonium	  acetate	  in	  95:5	  water	  :	  acetonitrile.	  	  Peak	  areas	  from	  the	  total	  ion	  current	  for	  each	  metabolite	  SRM	  transition	  were	  integrated	  using	  MultiQuant	  v1.1	  software	  (Applied	  Biosystems).	  	  Glucose-­‐13C	  labeled	  samples	  were	  run	  with	  249	  total	  SRM	  transitions	  (40	  in	  positive	  ion	  mode	  and	  209	  in	  negative	  ion	  mode)	  with	  a	  total	  cycle	  time	  of	  0.464	  seconds.	  	  	  	  
Isotope	  labeling	  and	  kinetic	  profiling	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Basal	  media	  using	  dialyzed	  serum	  without	  glucose	  was	  supplemented	  with	  [U13C]-­‐glucose	  (Cambridge	  Isotope	  Laboratories)	  to	  a	  concentration	  equivalent	  to	  the	  concentration	  suggested	  by	  ATCC	  protocol.	  	  Fresh	  media	  was	  added	  two	  hours	  prior	  to	  the	  kinetics	  experiment.	  	  Media	  was	  replaced	  by	  equivalent	  [U13C]-­‐glucose	  labeled	  media	  and	  cells	  quickly	  harvested	  at	  given	  time	  points	  using	  the	  above	  mentioned	  protocol.	  	  Steady-­‐state	  [U13C]-­‐glucose	  labeling	  involved	  labeling	  cells	  for	  12	  hours	  prior	  to	  metabolite	  extraction.	  	  Samples	  were	  prepared	  as	  described	  above.	  	  Data	  analysis	  was	  performed	  in	  Matlab.	  	  	  
Gas-­‐Chromatography	  Mass	  Spectrometry	  (GC/MS)	  	  	  	  
	  Cells	  were	  cultured	  in	  6	  well	  plates	  before	  replacing	  medium	  with	  DMEM	  containing	  10%	  dialyzed	  FBS	  and	  either	  [U-­‐13C]glucose	  +	  unlabeled	  glutamine	  or	  [α-­‐15N]glutamine	  and	  unlabeled	  glucose.	  	  After	  24	  hours,	  cells	  were	  rinsed	  with	  1	  ml	  ice	  cold	  PBS	  and	  quenched	  with	  0.4	  ml	  ice	  cold	  methanol.	  	  An	  equal	  volume	  of	  water	  was	  added,	  and	  cells	  were	  collected	  in	  tubes	  by	  scraping	  with	  a	  pipette.	  	  One	  volume	  of	  ice	  cold	  chloroform	  was	  added	  to	  each	  tube,	  and	  the	  extracts	  were	  vortexed	  at	  4°C	  for	  30	  minutes.	  	  Samples	  were	  centrifuged	  at	  14,000	  g	  for	  5	  minutes,	  and	  the	  aqueous	  phase	  was	  transferred	  to	  a	  new	  tube	  for	  evaporation	  under	  nitrogen	  airflow.	  	  
Derivatization	  and	  GC/MS	  measurements	  A	  two-­‐step	  derivitization	  method	  was	  used	  as	  previously	  described32.	  	  Dried	  polar	  metabolites	  were	  dissolved	  in	  20	  μl	  of	  2%	  methoxyamine	  hydrochloride	  in	  pyridine	  (Pierce)	  and	  held	  at	  37°C	  for	  1.5	  hours.	  	  After	  dissolution	  and	  reaction,	  tert-­‐butyldimethylsilyl	  (TBDMS)	  derivatization	  was	  initiated	  by	  adding	  30	  μl	  N-­‐methyl-­‐N-­‐	  (tert-­‐butyldimethylsilyl)trifluoroacetamide	  MBTSTFA	  +	  1%	  tert-­‐butyldimethylchlorosilane	  TBDMCS	  (Pierce)	  and	  incubating	  at	  55°C	  for	  60	  minutes.	  Gas	  chromatography/mass	  spectrometry	  (GC/MS)	  analysis	  was	  performed	  using	  an	  Agilent	  6890	  GC	  equipped	  with	  a	  30m	  DB-­‐35MS	  capillary	  column	  connected	  to	  an	  Agilent	  5975B	  MS	  operating	  under	  electron	  impact	  (EI)	  ionization	  at	  70	  eV.	  	  One	  μl	  of	  sample	  was	  injected	  in	  splitless	  mode	  at	  270°C,	  using	  helium	  as	  the	  carrier	  gas	  at	  a	  flow	  rate	  of	  1	  ml	  min-­‐1.	  	  The	  GC	  oven	  temperature	  was	  held	  at	  100°C	  for	  3	  min	  and	  increased	  to	  300°C	  at	  3.5°	  min-­‐1.	  	  The	  MS	  source	  and	  quadrupole	  were	  held	  at	  230°C	  and	  150°C,	  respectively,	  and	  the	  detector	  recorded	  ion	  abundance	  in	  the	  range	  of	  100	  –	  600	  m/z.	  	  Mass	  isotopomer	  distributions	  (MIDs)	  for	  serine	  and	  glycine	  were	  determined	  by	  integrating	  ion	  fragments	  of	  390	  –	  398	  m/z	  and	  246	  –	  252	  m/z,	  respectively.	  	  MIDs	  were	  corrected	  for	  natural	  isotope	  abundance	  using	  in	  house	  algorithms	  adapted	  from	  Fernandez	  et	  al.	  33.	  	  
Analysis	  of	  somatic	  copy	  number	  alterations	  of	  PHGDH	  	  Data	  processed	  in	  Matlab	  across	  3131	  total	  samples	  and	  150	  melanoma	  samples	  from	  the	  Broad	  Institute	  as	  previously	  compiled13.	  	  Heatmaps	  were	  generated	  in	  Matlab	  by	  first	  sorting	  copy	  number	  intensity	  at	  the	  coding	  region	  of	  PHGDH.	  	  False	  discovery	  rates	  (q-­‐values)	  on	  chromosome	  1p	  were	  computed	  using	  a	  background	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model	  previously	  developed	  and	  plotted	  in	  Matlab.	  	  q-­‐values	  for	  candidate	  oncogenes	  were	  reported	  as	  in	  a	  previous	  study13.	  	  
Cell	  proliferation	  assays	  	  Lentiviral	  infection	  and	  puromycin	  selection	  was	  carried	  out	  under	  established	  protocols.	  	  After	  puromycin	  selection,	  control	  and	  knockdown	  cells	  were	  plated	  at	  equal	  densities	  at	  initial	  densities	  were	  normalized	  to	  the	  intrinsic	  growth	  rate	  of	  each	  cell	  line	  and	  seeded	  cells	  allowed	  to	  grow	  for	  three	  days	  prior	  to	  counting.	  	  Cell	  numbers	  were	  counted	  on	  the	  final	  day	  using	  an	  automated	  cell	  counter	  (Cellometer	  Auto	  T4,	  Nexcelom	  Bioscience)	  with	  custom	  morphological	  parameters	  set	  for	  each	  cell	  line.	  	  Error	  bars	  were	  reported	  using	  error	  propagation	  from	  the	  standard	  deviation	  of	  three	  experiments.	  	  
3-­‐dimensional	  culture	  and	  confocal	  microscopy	  
	  To	  generate	  acini,	  cells	  were	  grown	  in	  reconstituted	  basement	  membrane	  (Matrigel)	  as	  described	  previously	  and	  according	  the	  protocol	  at	  http://brugge.med.harvard.edu/.	  	  The	  overlay	  media	  was	  changed	  every	  four	  days	  and	  a	  given	  concentration	  of	  doxycycline	  (Sigma)	  was	  added	  where	  indicated.	  Acini	  were	  fixed	  between	  days	  25	  and	  28	  and	  immunofluorescence	  analyses	  of	  acini	  was	  performed	  as	  described	  previously.	  	  The	  following	  primary	  antibodies	  were	  used	  for	  immunofluorescence:	  cleaved	  caspase-­‐3	  (#9661,	  Cell	  Signaling	  Technology)	  and	  laminin-­‐5	  (mab19562,	  Millipore,	  Billerica,	  MA).	  The	  golgi	  apparatus	  was	  detected	  combining	  antibodies	  to	  the	  golgi	  proteins	  GM130	  (610823,	  BD	  Biosciences)	  and	  Golgin-­‐84	  (51-­‐9001984,	  BD	  Biosciences).	  DAPI	  (Sigma-­‐Aldrich)	  was	  used	  to	  counterstain	  nuclei.	  	  For	  examination	  of	  luminal	  filling,	  acini	  were	  imaged	  using	  confocal	  microscopy	  to	  visualize	  the	  centre	  of	  each	  structure,	  and	  then	  were	  scored	  as	  clear	  (~90–100%	  clear),	  mostly	  clear	  (~50–90%	  clear),	  mostly	  filled	  (~10–50%	  clear),	  or	  clear	  (~0–10%	  clear).	  	  	  	  	  
Fluorescence	  in-­‐situ	  hybridization	  (FISH).	  	  	  	  Cultured	  cell	  lines	  were	  harvested	  at	  75%	  confluence	  and	  metaphase	  chromosome	  spreads	  were	  produced	  using	  conventional	  cytogenetic	  methods.	  	  Human	  melanoma	  tissue	  arrays	  were	  first	  heated	  to	  remove	  paraffin.	  	  Slides	  were	  aged	  overnight	  at	  37°C,	  dehydrated	  by	  successive	  two	  minute	  washes	  with	  70%,	  80%,	  90%	  and	  100%	  ethanol,	  air-­‐dried	  and	  then	  hybridized	  to	  DNA	  probes	  as	  described	  below.	  	  The	  following	  DNA	  probes	  were	  co-­‐hybridized:	  RP11-­‐22F13	  (labeled	  in	  SpectrumGreen),	  which	  maps	  to	  1p12	  and	  includes	  PHGDH,	  and	  the	  D1Z5	  alpha-­‐satellite	  probe	  (SpectrumOrange;	  Abbott	  Molecular,	  Inc.),	  which	  maps	  to	  1p11.1-­‐q11.1.	  The	  RP11-­‐22F13	  BAC	  clone	  was	  obtained	  from	  CHORI	  (www.chori.org),	  direct-­‐labeled	  using	  nick	  translation,	  and	  precipitated	  using	  standard	  protocols.	  Final	  probe	  concentration	  was	  100ng/ul.	  	  The	  final	  concentration	  used	  for	  the	  commercial	  probes	  followed	  manufacturer's	  recommendations.	  	  The	  tissue	  sections	  and	  probes	  were	  co-­‐denatured	  at	  80°C	  for	  5	  min,	  hybridized	  at	  least	  16	  hrs	  at	  37°C	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in	  a	  darkened	  humid	  chamber,	  washed	  in	  2X	  SSC	  at	  70°C	  for	  10	  min,	  rinsed	  in	  room	  temperature	  2X	  SSC,	  and	  counterstained	  with	  DAPI	  (4',6-­‐diamidino-­‐2-­‐phenylindole,	  Abbott	  Molecular/Vysis,	  Inc.).	  	  Slides	  were	  imaged	  using	  an	  Olympus	  BX51	  fluorescence	  microscope.	  	  Individual	  images	  were	  captured	  using	  an	  Applied	  Imaging	  system	  running	  CytoVision	  Genus	  version	  3.92.	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